[Correspondence] ALND after neoadjuvant chemotherapy: a call for caution

We read with interest the Article by Giacomo Montagna and colleagues1 evaluating oncological outcomes in patients with residual nodal micrometastatic disease (ypN1mi) following neoadjuvant systemic therapy. Although the study contributes important data on axillary management, the recommendation favouring completion axillary lymph node dissection (ALND) in patients with triple-negative breast cancer warrants cautious interpretation given key limitations and conflicting evidence.